LENZ Therapeutics (LENZ) Total Liabilities (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Total Liabilities of $26.0 million for Q1 2026, up 181.79% year-over-year from $9.2 million in Q1 2025, and up 20.92% quarter-over-quarter from $21.5 million in Q4 2025.
LENZ Therapeutics (LENZ) Total Liabilities (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Total Liabilities for 7 consecutive years, with $26.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 181.79% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at $26.0 million (up 181.79% YoY), while the FY2025 annual figure was $21.5 million, up 91.95% from the prior year.
- Total Liabilities climbed to $26.0 million in Q1 2026 per LENZ's latest filing, from $21.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $62.9 million in Q2 2023 and bottomed at $8.7 million in Q3 2024.
- Historically, Total Liabilities has averaged $22.9 million across 5 years, with a median of $18.4 million in 2022.
- Annual changes were most pronounced in 2023 — Total Liabilities soared 310.29% — and 2024, when it sank 85.97%.
- LENZ Therapeutics' Total Liabilities stood at $25.6 million in 2022, then decreased by 23.09% to $19.7 million in 2023, then sank by 43.04% to $11.2 million in 2024, then jumped by 91.95% to $21.5 million in 2025, then rose by 20.92% to $26.0 million in 2026.
- Business Quant data shows LENZ's Total Liabilities at $26.0 million in Q1 2026, $21.5 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 10.03 Bn |
| 10 | LENZ Therapeutics | 148.40 Mn | 148.40 Mn | 5.21 Mn | 17.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.33 Mn |
| Mar 31, 2026 | 26.04 Mn |
| Dec 31, 2025 | 21.54 Mn |
| Sep 30, 2025 | 16.78 Mn |
| Jun 30, 2025 | 10.97 Mn |
| Mar 31, 2025 | 9.24 Mn |
| Dec 31, 2024 | 11.22 Mn |
| Sep 30, 2024 | 8.73 Mn |
| Jun 30, 2024 | 9.72 Mn |
| Mar 31, 2024 | 19.16 Mn |
| Dec 31, 2023 | 19.70 Mn |
| Sep 30, 2023 | 62.21 Mn |
| Jun 30, 2023 | 62.90 Mn |
| Mar 31, 2023 | 33.77 Mn |
| Dec 31, 2022 | 25.61 Mn |
| Sep 30, 2022 | 18.39 Mn |
| Jun 30, 2022 | 15.33 Mn |
| Mar 31, 2022 | 17.31 Mn |
| Dec 31, 2021 | 17.94 Mn |
| Sep 30, 2021 | 16.02 Mn |